Literature DB >> 31155929

Endophthalmitis after dropless (Tri-Moxi injection) cataract surgery.

Caleb Ng1, Kakarla V Chalam1,2.   

Abstract

INTRODUCTION: A case of endophthalmitis after dropless cataract surgery with intravitreal Tri-Moxi associated with severe vision loss. CASE
SUMMARY: An 82-year-old male developed severe vision loss in the left eye 24 days after dropless cataract surgery with intravitreal Tri-Moxi injection. Best corrected visual acuity was hand motion in the left eye. Intraocular pressure was 13, with inferior keratic precipitates, 4 + cell with 1 mm layered hypopyon, and a plaque on the posterior capsule that blocked direct exam of the posterior segment. Ultrasonography revealed extensive vitritis without retinal or choroidal detachments.
CONCLUSION: Endophthalmitis resolved and vision improved after management with vitreous tap, intravitreal and fortified topical antibiotics, and subsequent prompt pars plana vitrectomy. Vitreous sample grew fluoroquinolone-resistant staphylococcus epidermidis.

Entities:  

Keywords:  Dropless cataract surgery; Tri-Moxi; endophthalmitis; intravitreal injection

Mesh:

Substances:

Year:  2019        PMID: 31155929     DOI: 10.1177/1120672119852505

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  2 in total

1.  Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018.

Authors:  Penny A Asbell; Christine M Sanfilippo; Daniel F Sahm; Heleen H DeCory
Journal:  JAMA Ophthalmol       Date:  2020-05-01       Impact factor: 7.389

2.  Comparative Outcomes of Standard Perioperative Eye Drops, Intravitreal Triamcinolone Acetonide-Moxifloxacin, and Intracameral Dexamethasone-Moxifloxacin-Ketorolac in Cataract Surgery.

Authors:  Robin K Kuriakose; Soungmin Cho; Saman Nassiri; Frank S Hwang
Journal:  J Ophthalmol       Date:  2022-07-19       Impact factor: 1.974

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.